NEWS

IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down – Xconomy

2018-05-31 Michael Zand NEWS

Janssen begins phase 1b/2 clinical trial to assess multiple myeloma … – Pharmaceutical Business Review

IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down
Xconomy
They were a top choice to combine with the powerful but limited immunotherapies that have emerged this decade to fight many types of cancer. IDO inhibitors would broaden immunotherapy’s reach, the thinking went. “Everything is starting to come together …

2018-05-31 Michael Zand NEWS

Synthetic biology hacks the code for sustainability – GreenBiz

GreenBizSynthetic biology hacks the code for sustainabilityGreenBizToday, synthetic biology — "synbio," for short — is rapidly growing, with great promise for addressing a wide range of sustainability issues, including how we power and feed o… Continue reading

2018-05-31 Michael Zand NEWS

ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to NMI and NMI TT Pharmaservices – Business Wire (press release)

Business Wire (press release)ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to NMI and NMI TT PharmaservicesBusiness Wire (press release)ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentie… Continue reading

2018-05-31 Michael Zand NEWS

Stem cell bank opens with backing from leading scientists – Stat – STAT

Janssen begins phase 1b/2 clinical trial to assess multiple myeloma …
Pharmaceutical Business Review
Janssen has commenced a phase 1b/2 clinical development program to assess JNJ-68284528 (developed based on Legend’s LCAR-B38M), a chimeric …

and more »

2018-05-31 Michael Zand NEWS

Mesoblast and Cartherics form partnership to develop ‘off-the-shelf’ CAR-T therapies for solid cancers – News-Medical.net

STAT

Stem cell bank opens with backing from leading scientists – Stat
STAT
The company’s sales pitch has raised eyebrows among outside experts — especially considering the pedigree of its advisers and their history of speaking out …
Some blood stem cells are better than othersScience Daily
Global Stem Cell Banking Market Expected to Reach $6956 Million by 2023, Says Allied Market ResearchPR Newswire (press release)
Study shows blood stem cells compensate for immune cell deficienciesNews-Medical.net
PR Newswire UK (press release)
all 235 news articles »

2018-05-31 Michael Zand NEWS

Mesoblast and Cartherics form partnership to develop ‘off-the-shelf’ CAR-T therapies for solid cancers – News-Medical.net

News-Medical.net

Mesoblast and Cartherics form partnership to develop ‘off-the-shelf’ CAR–T therapies for solid cancers
News-Medical.net
Relapsed Ovarian and Gastric Cancers Initial Targets for Allogeneic CAR–T Cells. Mesoblast Limited today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR–T cells armed with multiple …

2018-05-31 Michael Zand NEWS

1
…
30
31
32
33
34
…
3,595

News-Medical.net

Login

Cart

Top Growing Trends & Segments in Global Synthetic Biology Market, 2016-2024 – Clean Technology

IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down – Xconomy

Janssen begins phase 1b/2 clinical trial to assess multiple myeloma … – Pharmaceutical Business Review

Synthetic biology hacks the code for sustainability – GreenBiz

ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to NMI and NMI TT Pharmaservices – Business Wire (press release)

Stem cell bank opens with backing from leading scientists – Stat – STAT

Mesoblast and Cartherics form partnership to develop ‘off-the-shelf’ CAR-T therapies for solid cancers – News-Medical.net

Mesoblast and Cartherics form partnership to develop ‘off-the-shelf’ CAR-T therapies for solid cancers – News-Medical.net

Recent Posts

Blog Categories

Blog Categories

Blog Categories

Blog Categories

Blog Categories